Trending Now - Revolutionary GLP-1 Pill Promises Wider Weight-loss Access
WHO:
ABC News Business - U.S. health officials are involved in the approval of Eli Lilly's weight-loss pill.
Vox - Eli Lilly is the pharmaceutical company that developed the GLP-1 oral pill.
WHAT:
NBC News Health - Foundayo is a new GLP-1 daily pill that will be available for purchase starting on April 7th, 2026.
Fox News Health - Clinical trials for Foundayo indicated that adults lost an average of 27.3 pounds on the highest dose, with reported side effects.
Fox News - Clinical trials for Foundayo showed that adults lost an average of 27.3 pounds on the highest dose.
NBC News Health - Foundayo is set to hit the market on April 7th, 2026.
NBC News Health - The approval of Foundayo follows the approval of Novo Nordisk's Wegovy pill in December 2025.
CBS News US - The FDA's approval of Eli Lilly's GLP-1 drug is part of a broader trend in obesity treatment options.
Inc - Foundayo can be taken anytime, eliminating the need for injections, fasting windows, and strict dosing routines.
Men's Health - Foundayo is reported to have similar efficacy to other GLP-1 drugs but is noted to be easier to take.
Vox - The Food and Drug Administration (FDA) has approved Eli Lilly’s GLP-1 oral pill for sale in the United States.
Newsweek - The drug will be sold under the brand name Foundayo and is a daily weight-loss pill.
Newsweek - Foundayo is a fast-tracked GLP-1 drug that offers a new option for obesity treatment.
WHERE:
Vox - The approval is for sale in the United States.
WHEN:
Vox - The FDA approval occurred on March 31st, 2026.
WHY:
NY Post - The new GLP-1 pill is reported to promise greater flexibility compared to its predecessor, Wegovy, with similar, if slightly less drastic, weight-trimming results.
NY Post - The new GLP-1 drug from Eli Lilly is not only effective for diabetes but also facilitates significant weight loss, indicating its dual purpose.
NY Post - The new GLP-1 drug from Eli Lilly is reported to help patients lose a quarter of their body weight, indicating its effectiveness beyond diabetes treatment.
NY Post - The new GLP-1 drug from Eli Lilly has been shown to help patients lose a quarter of their body weight, indicating its effectiveness beyond diabetes treatment.
Newsweek - The approval of Foundayo is expected to expand access for millions of Americans seeking obesity treatment.
HOW:
Vox - The approval of Foundayo represents a significant advancement in the development of oral GLP-1 medications.
Vox - The approval marks an important technological inflection point for the class of GLP-1 drugs.
(UPDATED April 2, 2026 19:17 UTC)
Foundayo, a new GLP-1 daily pill, will be available for purchase starting April 7th. Clinical trials for Foundayo showed that adults lost an average of 27.3 pounds on the highest dose, although there were some reported side effects. This new medication is generating interest as it approaches its release date.
--
(UPDATED April 2, 2026 17:15 UTC)
Clinical trials for Foundayo have shown that adults lost an average of 27.3 pounds on the highest dose of the new GLP-1 pill. This medication is reported to offer greater flexibility compared to its predecessor, Wegovy, while still delivering similar, though slightly less drastic, weight-trimming results. As interest in weight management solutions continues to grow, these findings could have significant implications for those seeking effective options.
--
(UPDATED April 2, 2026 13:19 UTC)
Foundayo is set to hit the market April 7th, following its recent approval. This comes on the heels of Novo Nordisk's Wegovy pill, which received approval in December 20th25. Both medications are part of the growing landscape of treatments aimed at addressing health concerns.
--
(UPDATED April 2, 2026 03:50 UTC)
U.S. health officials are currently involved in the approval process for Eli Lilly's new weight-loss pill, which is part of a broader trend in obesity treatment options. This GLP-1 drug is not only effective for managing diabetes but also promotes significant weight loss, showcasing its dual purpose. The approval of this medication marks a significant advancement in the development of oral GLP-1 treatments.
--
(UPDATED April 2, 2026 01:21 UTC)
Eli Lilly's new GLP-1 drug is making headlines for its impressive ability to help patients lose a quarter of their body weight, showcasing its effectiveness beyond just diabetes treatment. This development was reported by the New York Post at 19:23 UTC. The drug's potential impact on weight management could change the landscape of obesity treatment.
--
(UPDATED April 1, 2026 23:08 UTC)
Foundayo has introduced a new product that can be taken at any time, which eliminates the need for injections, fasting windows, and strict dosing routines. This innovative approach offers a more flexible option for those managing their health. The announcement was made at 23:08 UTC.
--
(UPDATED April 1, 2026 21:11 UTC)
Eli Lilly's new GLP-1 drug, Foundayo, has been reported to have similar efficacy to other medications in its class but is noted for being easier to take. This drug has shown the potential to help patients lose a quarter of their body weight, highlighting its effectiveness beyond just diabetes treatment. As a result, it could become a significant option for those looking to manage their weight more effectively.
--
(UPDATED April 1, 2026 19:23 UTC)
The Food and Drug Administration has approved Eli Lilly’s GLP-1 oral pill for sale in the United States, which will be marketed under the brand name Foundayo. This daily weight-loss pill represents a significant advancement in obesity treatment options and is expected to expand access for millions of Americans seeking help. The FDA approval was granted on Tuesday, marking an important technological milestone for the class of GLP-1 drugs.